SCHEMBL3556920

SCHEMBL3556920

COC(=O)c1ccc2c([N+](=O)[O-])cc3c(c2c1)C(CCl)CN3C(=O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 4/20 0.37
VCAM1 P19320 1/20 0.37
ALDH1A1 P00352 5/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GAA P10253 1/20 0.35
WDR5 P61964 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ADH1A P07327 1/20 0.35
KIT P10721 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565156 0.91 ADH1A (0.36) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL3885928 0.87 ADH1A (0.38) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL3564653 0.85 ADH1A (0.49) MEN1KMT2AHPGDALDH1A1MAPT
SCHEMBL3555079 0.83 CA2 (0.42) KMT2AHPGDVCAM1ALDH1A1MAPT
SCHEMBL3559992 0.82 ADH1A (0.37) SMN1; SMN2HPGDALDH1A1MAPTKDM4E
SCHEMBL13345017 0.81 ADH1A (0.33) ADH1AKITFLT1FLT4KDR
SCHEMBL3566213 0.80 ADH1A (0.38) HPGDALDH1A1MAPTADH1AKIT
SCHEMBL3558308 0.79 ADH1A (0.36) ADH1AKITFLT1FLT4KDR
SCHEMBL3562630 0.79 SIRT6 (0.36) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL3562214 0.79 CA2 (0.42) KMT2AVCAM1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A SMN1; SMN2 4797/4885MEN1 3844/4885KMT2A 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.